Multi-level complexities in technological development: Competing strategies for drug discovery
| Abstract | Drug development regularly has to deal with complex circumstances on two levels: the local level of pharmacological intervention on specific target proteins, and the systems level of the effects of pharmacological intervention on the organism. Different development strategies in the recent history of early drug development can be understood as competing attempts at coming to grips with these multi-level complexities. Both rational drug design and high-throughput screening concentrate on the local level, while traditional empirical search strategies as well as recent systems biology approaches focus on the systems level. The analysis of these strategies reveals serious obstacles to integrating the study of interventive and systems complexity in a systematic, methodical way. Due to some fairly general properties of biological networks and the available options for pharmaceutical intervention, drug development is captured in an obstinate methodological dilemma. It is argued that at least in typical cases, drug development therefore remains dependent on coincidence, serendipity or plain luck to bridge the gap between (empirical and/or rational) development methodology and actual therapeutic success. | |||||||||
| Keywords | No keywords specified (fix it) | |||||||||
| Categories | No categories specified (fix it) | |||||||||
| Options |
|
|||||||||
Download options| PhilPapers Archive |
Upload a copy of this paper Check publisher's policy on self-archival Papers currently archived: 5,653 |
| External links |
  Try with proxy. |
| Through your library | Only published papers are available at libraries |
Similar books and articlesRinaldo B. Schinazi (2006). The Probability of Treatment Induced Drug Resistance. Acta Biotheoretica 54 (1).
Thomas C. Jones (2005). A Call to Restructure the Drug Development Process: Government Over-Regulation and Non-Innovative Late Stage (Phase III) Clinical Trials Are Major Obstacles to Advances in Health Care. Science and Engineering Ethics 11 (4):575-587.
Sharie McNamee (1977). Moral Behaviour, Moral Development and Motivation. Journal of Moral Education 7 (1):27-31.
Laurence J. Hirsch (2002). Conflicts of Interest in Drug Development: The Practices of Merck & Co., Inc. Science and Engineering Ethics 8 (3).
William C. Buhles (2011). Compassionate Use A Story of Ethics and Science in the Development of a New Drug. Perspectives in Biology and Medicine 54 (3):304-315.
Pio García (2009). Discovery by Serendipity: A New Context for an Old Riddle. Foundations of Chemistry 11 (1).
Matthias Adam (2005). Integrating Research and Development: The Emergence of Rational Drug Design in the Pharmaceutical Industry. Studies in History and Philosophy of Science Part C 36 (3):513-537.
Analytics
Monthly downloads
Sorry, there are not enough data points to plot this chart.
|
Added to index2009-04-15Total downloads4 ( #178,434 of 548,977 )Recent downloads (6 months)0How can I increase my downloads? |
My notes
Discussion
